Active Ingredient History
Glycine (Cly) is a natural amino acid neurotransmitter that acts as a co-agonist at Glutamate [NMDA] receptors in the brain and is an activator of glycine receptors, GLRA1-3, GLRB. The abnormal Gly levels have been implicated in neuropsychiatric disorders. Alterations in Gly levels are implicated in several diseases of the central nervous system. Glycine was studied in phase II of clinical trials in patients with schizophrenia. The results have shown that using of glycine was associated with reduced symptoms with promising effect sizes and a possibility of improvement in cognitive function. Besides, glycine was also studied in clinical trials phase II in children with cystic fibrosis. The clinical, spirometric and inflammatory status of subjects with cystic fibrosis improved after just 8 weeks of glycine intake, suggesting that this amino acid might constitute a novel therapeutic tool for these patients. In addition, Gly was proposed as a biomarker for brain tumor malignancy. Glycine is a component of a nutrients mixture for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Malnutrition (approved 1971)
Aging (Phase 1)
Airway Management (Phase 2)
Alcoholism (Phase 2)
Alzheimer Disease (Early Phase 1)
Arthroplasty, Replacement, Knee (Phase 4)
Asthma (Phase 1/Phase 2)
Atherosclerosis (Phase 2/Phase 3)
Bipolar Disorder (Phase 2)
Cognitive Dysfunction (Early Phase 1)
COVID-19 (Phase 2)
Cystic Fibrosis (Phase 2)
Diabetes Mellitus (Phase 2/Phase 3)
Diarrhea (Phase 3)
Dyslipidemias (Phase 2/Phase 3)
Erythrocytes, Abnormal (Phase 1)
Fasting (Phase 1)
Growth Hormone (Phase 3)
Healthy Volunteers (Phase 1/Phase 2)
Herpes Labialis (Phase 2)
HIV Infections (Phase 1)
Hypertension (Phase 2)
Malnutrition (Phase 3)
Metabolic Syndrome (Phase 2/Phase 3)
Muscle Weakness (Phase 1)
Obesity (Phase 2/Phase 3)
Osteoarthritis, Knee (Phase 4)
Pain, Postoperative (Phase 4)
Prader-Willi Syndrome (Phase 3)
Psychotic Disorders (Phase 2/Phase 3)
Schizophrenia (Phase 3)
Simplexvirus (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
